| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Cell Lung Carcinoma | 23 | 2024 | 408 | 4.110 |
Why?
|
| Lung Neoplasms | 89 | 2024 | 11761 | 2.630 |
Why?
|
| Carcinoma, Small Cell | 21 | 2006 | 427 | 2.110 |
Why?
|
| Head and Neck Neoplasms | 52 | 2021 | 4124 | 2.050 |
Why?
|
| Carcinoma, Squamous Cell | 58 | 2023 | 5568 | 2.040 |
Why?
|
| Etoposide | 35 | 2024 | 905 | 1.730 |
Why?
|
| Cisplatin | 52 | 2024 | 2493 | 1.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 70 | 2024 | 16593 | 1.660 |
Why?
|
| Salivary Gland Neoplasms | 8 | 2021 | 499 | 1.200 |
Why?
|
| Carcinoma, Neuroendocrine | 9 | 2024 | 741 | 1.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 43 | 2024 | 5517 | 1.060 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 667 | 1.020 |
Why?
|
| Camptothecin | 7 | 2010 | 538 | 0.990 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2022 | 1335 | 0.950 |
Why?
|
| Papillomavirus Infections | 5 | 2023 | 1009 | 0.930 |
Why?
|
| Taxoids | 16 | 2019 | 1008 | 0.920 |
Why?
|
| Neoplasm Recurrence, Local | 37 | 2021 | 10349 | 0.920 |
Why?
|
| Induction Chemotherapy | 9 | 2021 | 671 | 0.910 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2021 | 1088 | 0.880 |
Why?
|
| Carcinoma, Adenoid Cystic | 5 | 2023 | 445 | 0.870 |
Why?
|
| Antibodies, Monoclonal, Humanized | 18 | 2023 | 3397 | 0.860 |
Why?
|
| Oropharyngeal Neoplasms | 9 | 2023 | 1157 | 0.860 |
Why?
|
| Antineoplastic Agents | 34 | 2019 | 14679 | 0.820 |
Why?
|
| Human papillomavirus 16 | 2 | 2022 | 256 | 0.750 |
Why?
|
| Skin Neoplasms | 13 | 2021 | 4840 | 0.740 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2018 | 397 | 0.730 |
Why?
|
| Nasopharyngeal Neoplasms | 7 | 2015 | 337 | 0.720 |
Why?
|
| Paclitaxel | 24 | 2019 | 2099 | 0.690 |
Why?
|
| Aged | 122 | 2024 | 73160 | 0.680 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 254 | 0.670 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 13976 | 0.670 |
Why?
|
| Cetuximab | 6 | 2019 | 473 | 0.660 |
Why?
|
| Middle Aged | 133 | 2024 | 90020 | 0.640 |
Why?
|
| Quinazolines | 8 | 2024 | 953 | 0.640 |
Why?
|
| Humans | 202 | 2024 | 270946 | 0.610 |
Why?
|
| Antineoplastic Agents, Phytogenic | 11 | 2009 | 896 | 0.600 |
Why?
|
| Maximum Tolerated Dose | 12 | 2016 | 1323 | 0.580 |
Why?
|
| Male | 136 | 2024 | 128453 | 0.560 |
Why?
|
| Adult | 109 | 2024 | 81555 | 0.560 |
Why?
|
| Genes, myb | 1 | 2016 | 13 | 0.550 |
Why?
|
| Female | 147 | 2024 | 148508 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 11 | 2023 | 4510 | 0.540 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 196 | 0.530 |
Why?
|
| Gene Fusion | 1 | 2016 | 213 | 0.480 |
Why?
|
| Immunotherapy | 6 | 2024 | 3532 | 0.480 |
Why?
|
| Carcinoma | 9 | 2020 | 2627 | 0.480 |
Why?
|
| Carboplatin | 10 | 2019 | 879 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2021 | 4956 | 0.460 |
Why?
|
| Piperazines | 6 | 2019 | 2153 | 0.460 |
Why?
|
| Laryngeal Neoplasms | 6 | 2021 | 532 | 0.450 |
Why?
|
| Alphapapillomavirus | 1 | 2015 | 174 | 0.450 |
Why?
|
| ErbB Receptors | 13 | 2021 | 2379 | 0.430 |
Why?
|
| DNA Topoisomerases, Type II | 11 | 1992 | 126 | 0.420 |
Why?
|
| Neutropenia | 12 | 2010 | 1001 | 0.420 |
Why?
|
| Neoplasms | 8 | 2020 | 15849 | 0.420 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 750 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 13 | 2024 | 5188 | 0.420 |
Why?
|
| Treatment Outcome | 49 | 2021 | 33827 | 0.410 |
Why?
|
| Disease-Free Survival | 27 | 2020 | 10250 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2021 | 5411 | 0.390 |
Why?
|
| B7-H1 Antigen | 5 | 2021 | 1057 | 0.390 |
Why?
|
| Survival Rate | 35 | 2024 | 12516 | 0.370 |
Why?
|
| Carcinoma, Large Cell | 3 | 2024 | 96 | 0.370 |
Why?
|
| Survival Analysis | 26 | 2021 | 9307 | 0.360 |
Why?
|
| Autocrine Communication | 1 | 2010 | 93 | 0.350 |
Why?
|
| Carcinoma, Ductal | 2 | 2021 | 144 | 0.350 |
Why?
|
| Aged, 80 and over | 43 | 2021 | 30940 | 0.350 |
Why?
|
| Chemoradiotherapy | 7 | 2021 | 2029 | 0.350 |
Why?
|
| Pyridines | 6 | 2019 | 1311 | 0.350 |
Why?
|
| Ifosfamide | 12 | 2009 | 357 | 0.340 |
Why?
|
| Drug Therapy | 2 | 2009 | 207 | 0.330 |
Why?
|
| Prognosis | 32 | 2024 | 22458 | 0.330 |
Why?
|
| Immunity | 2 | 2022 | 356 | 0.330 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2015 | 85 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2020 | 5108 | 0.320 |
Why?
|
| Pyrimidines | 6 | 2020 | 3667 | 0.320 |
Why?
|
| Benzodiazepinones | 2 | 2019 | 12 | 0.320 |
Why?
|
| Podophyllotoxin | 7 | 1987 | 65 | 0.320 |
Why?
|
| Phthalazines | 4 | 2019 | 262 | 0.310 |
Why?
|
| Maxillary Sinus Neoplasms | 2 | 2020 | 116 | 0.310 |
Why?
|
| Biomarkers, Tumor | 17 | 2024 | 10698 | 0.300 |
Why?
|
| Drug Administration Schedule | 16 | 2015 | 3542 | 0.300 |
Why?
|
| Disease Progression | 13 | 2020 | 6893 | 0.290 |
Why?
|
| Combined Modality Therapy | 31 | 2019 | 9043 | 0.280 |
Why?
|
| Eyelid Neoplasms | 2 | 2019 | 197 | 0.280 |
Why?
|
| Mutation | 18 | 2024 | 15854 | 0.280 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 271 | 0.280 |
Why?
|
| Anilides | 2 | 2019 | 295 | 0.270 |
Why?
|
| Fluorouracil | 12 | 2019 | 1985 | 0.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2010 | 770 | 0.270 |
Why?
|
| HLA Antigens | 3 | 2021 | 575 | 0.260 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 5 | 2019 | 513 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2019 | 288 | 0.260 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 1985 | 0.260 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2021 | 285 | 0.250 |
Why?
|
| Smoking | 6 | 2017 | 2425 | 0.250 |
Why?
|
| Neoplasm Metastasis | 13 | 2019 | 5324 | 0.240 |
Why?
|
| Remission Induction | 13 | 2015 | 3645 | 0.240 |
Why?
|
| Immunoconjugates | 2 | 2019 | 315 | 0.240 |
Why?
|
| Larynx | 3 | 2021 | 143 | 0.230 |
Why?
|
| Organ Sparing Treatments | 3 | 2016 | 280 | 0.230 |
Why?
|
| Retrospective Studies | 32 | 2023 | 39694 | 0.230 |
Why?
|
| Salvage Therapy | 6 | 2019 | 2117 | 0.230 |
Why?
|
| DNA Damage | 5 | 2019 | 1980 | 0.220 |
Why?
|
| Lymph Nodes | 4 | 2020 | 3067 | 0.220 |
Why?
|
| Papillomaviridae | 5 | 2023 | 642 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2019 | 2953 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 2168 | 0.220 |
Why?
|
| Mice, Nude | 11 | 2021 | 4360 | 0.210 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 3928 | 0.210 |
Why?
|
| Deoxycytidine | 6 | 2019 | 1377 | 0.210 |
Why?
|
| Chromosome Fragility | 1 | 2002 | 33 | 0.210 |
Why?
|
| Immunotoxins | 1 | 2003 | 120 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 7 | 2020 | 2399 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2020 | 2266 | 0.210 |
Why?
|
| Follow-Up Studies | 20 | 2020 | 15253 | 0.200 |
Why?
|
| Paranasal Sinuses | 1 | 2022 | 64 | 0.200 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2013 | 360 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 1293 | 0.200 |
Why?
|
| Neck Dissection | 6 | 2021 | 294 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2020 | 3972 | 0.200 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2013 | 140 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 370 | 0.200 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 257 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1654 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2012 | 155 | 0.200 |
Why?
|
| Genes, erbB | 1 | 2021 | 27 | 0.200 |
Why?
|
| Tongue Neoplasms | 2 | 2018 | 252 | 0.190 |
Why?
|
| Amsacrine | 5 | 1989 | 63 | 0.190 |
Why?
|
| Feasibility Studies | 6 | 2018 | 2346 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2008 | 366 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 323 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 1004 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 2 | 2022 | 651 | 0.170 |
Why?
|
| Receptor, ErbB-2 | 4 | 2021 | 2648 | 0.170 |
Why?
|
| Lymphatic Metastasis | 11 | 2021 | 4968 | 0.170 |
Why?
|
| Ipilimumab | 2 | 2023 | 758 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2018 | 163 | 0.170 |
Why?
|
| Orbit Evisceration | 1 | 2019 | 47 | 0.170 |
Why?
|
| Nasal Surgical Procedures | 1 | 2019 | 10 | 0.160 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 14864 | 0.160 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 485 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2024 | 5494 | 0.160 |
Why?
|
| Time Factors | 8 | 2020 | 13112 | 0.160 |
Why?
|
| Intercalating Agents | 3 | 1987 | 32 | 0.160 |
Why?
|
| Acrylamides | 1 | 2018 | 69 | 0.160 |
Why?
|
| Mesothelioma | 2 | 2020 | 558 | 0.160 |
Why?
|
| Drug Approval | 1 | 2019 | 179 | 0.150 |
Why?
|
| CD56 Antigen | 1 | 2018 | 85 | 0.150 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2018 | 113 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1467 | 0.150 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 165 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2019 | 3920 | 0.150 |
Why?
|
| DNA, Neoplasm | 5 | 2018 | 1961 | 0.150 |
Why?
|
| Thiazoles | 2 | 2012 | 729 | 0.150 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 143 | 0.140 |
Why?
|
| Eyelids | 1 | 2018 | 154 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 7 | 2019 | 5834 | 0.140 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 232 | 0.140 |
Why?
|
| Aniline Compounds | 1 | 2018 | 206 | 0.140 |
Why?
|
| Adenoviridae | 5 | 2012 | 1510 | 0.140 |
Why?
|
| Animals | 25 | 2024 | 62771 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 169 | 0.140 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 172 | 0.130 |
Why?
|
| Adenocarcinoma | 7 | 2021 | 7936 | 0.130 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2017 | 115 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 707 | 0.130 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2016 | 84 | 0.130 |
Why?
|
| Tumor Burden | 6 | 2021 | 2034 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 732 | 0.130 |
Why?
|
| Genes, p53 | 4 | 2003 | 1133 | 0.130 |
Why?
|
| raf Kinases | 1 | 2015 | 81 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 220 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 721 | 0.120 |
Why?
|
| Apoptosis | 7 | 2019 | 7847 | 0.120 |
Why?
|
| Gene Transfer Techniques | 7 | 2012 | 812 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 649 | 0.120 |
Why?
|
| Topotecan | 4 | 2004 | 248 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 640 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 435 | 0.120 |
Why?
|
| Interferon-gamma | 2 | 2021 | 1184 | 0.120 |
Why?
|
| Drug Resistance | 6 | 1995 | 615 | 0.120 |
Why?
|
| Tretinoin | 3 | 1997 | 621 | 0.120 |
Why?
|
| Loss of Heterozygosity | 3 | 2021 | 624 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 670 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 3657 | 0.120 |
Why?
|
| Immunohistochemistry | 8 | 2020 | 7813 | 0.120 |
Why?
|
| Signal Transduction | 6 | 2021 | 12206 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1998 | 609 | 0.120 |
Why?
|
| Prospective Studies | 8 | 2020 | 13351 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 1725 | 0.120 |
Why?
|
| Infusions, Intravenous | 5 | 2003 | 1438 | 0.110 |
Why?
|
| Leukemia L1210 | 5 | 1987 | 57 | 0.110 |
Why?
|
| src-Family Kinases | 2 | 2013 | 487 | 0.110 |
Why?
|
| Integrin beta3 | 1 | 2013 | 47 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 2670 | 0.110 |
Why?
|
| Vinblastine | 3 | 2010 | 462 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 1014 | 0.110 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 703 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 505 | 0.110 |
Why?
|
| Deglutition | 2 | 2012 | 187 | 0.110 |
Why?
|
| Administration, Oral | 5 | 2018 | 1620 | 0.110 |
Why?
|
| Piperidines | 3 | 2009 | 1089 | 0.110 |
Why?
|
| Speech | 2 | 2012 | 139 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 99 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 686 | 0.100 |
Why?
|
| Radiation-Protective Agents | 2 | 2004 | 129 | 0.100 |
Why?
|
| DNA Repair | 3 | 2018 | 1886 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2004 | 2633 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2018 | 701 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1994 | 320 | 0.100 |
Why?
|
| Cohort Studies | 7 | 2021 | 9433 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 9078 | 0.100 |
Why?
|
| Drug Synergism | 6 | 2017 | 1369 | 0.100 |
Why?
|
| DNA, Single-Stranded | 2 | 1992 | 124 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2018 | 1571 | 0.100 |
Why?
|
| Salivary Glands | 2 | 2020 | 141 | 0.100 |
Why?
|
| Biological Transport | 2 | 2009 | 647 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2018 | 6837 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 2093 | 0.100 |
Why?
|
| Physicians | 1 | 2020 | 871 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 486 | 0.100 |
Why?
|
| Cyclosporine | 1 | 1992 | 295 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2618 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 475 | 0.100 |
Why?
|
| Salivary Ducts | 2 | 2021 | 55 | 0.090 |
Why?
|
| ras Proteins | 1 | 2015 | 803 | 0.090 |
Why?
|
| Mice | 16 | 2024 | 35992 | 0.090 |
Why?
|
| Genetic Therapy | 5 | 2012 | 1732 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 445 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 2669 | 0.090 |
Why?
|
| Imatinib Mesylate | 2 | 2006 | 1691 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 551 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2012 | 1742 | 0.090 |
Why?
|
| Esophagitis | 4 | 2012 | 210 | 0.090 |
Why?
|
| Laryngectomy | 3 | 2012 | 243 | 0.090 |
Why?
|
| Orbital Neoplasms | 1 | 2012 | 238 | 0.090 |
Why?
|
| Genotype | 2 | 2019 | 4109 | 0.090 |
Why?
|
| Genomics | 4 | 2024 | 2817 | 0.090 |
Why?
|
| Daunorubicin | 2 | 1992 | 313 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2012 | 419 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 2335 | 0.090 |
Why?
|
| DNA | 4 | 1986 | 3074 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 104 | 0.090 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 50 | 0.090 |
Why?
|
| Radiotherapy Dosage | 9 | 2012 | 4002 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 196 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 2471 | 0.090 |
Why?
|
| Proton Therapy | 1 | 2020 | 1638 | 0.080 |
Why?
|
| Radiation Injuries | 3 | 2009 | 1472 | 0.080 |
Why?
|
| Benzamides | 2 | 2006 | 1883 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 635 | 0.080 |
Why?
|
| Young Adult | 10 | 2020 | 22059 | 0.080 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 106 | 0.080 |
Why?
|
| Genes, ras | 1 | 2012 | 680 | 0.080 |
Why?
|
| DNA Mutational Analysis | 4 | 2018 | 2351 | 0.080 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2008 | 13 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2198 | 0.080 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2005 | 91 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 199 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6248 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 627 | 0.070 |
Why?
|
| Doxorubicin | 6 | 2000 | 3138 | 0.070 |
Why?
|
| Cricetinae | 5 | 1992 | 792 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2021 | 1187 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 1998 | 3075 | 0.070 |
Why?
|
| Glioma | 1 | 2018 | 1969 | 0.070 |
Why?
|
| Thrombocytopenia | 5 | 1998 | 872 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 3 | 2008 | 1379 | 0.070 |
Why?
|
| Trastuzumab | 3 | 2004 | 736 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2125 | 0.070 |
Why?
|
| Anemia | 2 | 2010 | 730 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 2368 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2618 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 5085 | 0.070 |
Why?
|
| Lymphocyte Activation | 4 | 2019 | 1733 | 0.070 |
Why?
|
| Cell Survival | 6 | 2015 | 3081 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2003 | 345 | 0.070 |
Why?
|
| Cranial Irradiation | 4 | 2003 | 322 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2004 | 1836 | 0.070 |
Why?
|
| Interferon-alpha | 4 | 2002 | 960 | 0.070 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 1990 | 35 | 0.060 |
Why?
|
| Diarrhea | 1 | 2009 | 731 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5523 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1603 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 3459 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1994 | 2123 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2008 | 1345 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2006 | 157 | 0.060 |
Why?
|
| Risk Factors | 6 | 2020 | 17823 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 1599 | 0.060 |
Why?
|
| Pyrazines | 2 | 2019 | 524 | 0.060 |
Why?
|
| Proteomics | 1 | 2012 | 1435 | 0.060 |
Why?
|
| Radiation Pneumonitis | 2 | 2004 | 313 | 0.060 |
Why?
|
| Cytokines | 2 | 2010 | 2836 | 0.060 |
Why?
|
| Pemetrexed | 2 | 2019 | 100 | 0.060 |
Why?
|
| Treatment Failure | 4 | 2019 | 1433 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 1084 | 0.060 |
Why?
|
| Indoles | 2 | 2024 | 1035 | 0.060 |
Why?
|
| Retreatment | 2 | 2019 | 451 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1522 | 0.060 |
Why?
|
| Genetic Vectors | 5 | 2003 | 1884 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 2 | 2019 | 180 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 491 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2013 | 2314 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 1987 | 791 | 0.050 |
Why?
|
| Cricetulus | 4 | 1987 | 215 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 7783 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2003 | 67 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 898 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 2003 | 3862 | 0.050 |
Why?
|
| Chromosome Fragile Sites | 1 | 2002 | 38 | 0.050 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 574 | 0.050 |
Why?
|
| Aminoacridines | 3 | 1986 | 23 | 0.050 |
Why?
|
| Benzimidazoles | 2 | 2015 | 441 | 0.050 |
Why?
|
| Adolescent | 9 | 2017 | 32577 | 0.050 |
Why?
|
| Radiotherapy | 3 | 2004 | 1858 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2002 | 56 | 0.050 |
Why?
|
| Hypopharynx | 1 | 2021 | 22 | 0.050 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2002 | 165 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 5990 | 0.050 |
Why?
|
| Tea | 1 | 2001 | 43 | 0.050 |
Why?
|
| Vomiting | 2 | 2005 | 361 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5233 | 0.050 |
Why?
|
| Nausea | 2 | 2005 | 540 | 0.050 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2001 | 63 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 3545 | 0.050 |
Why?
|
| Drug Antagonism | 2 | 2011 | 33 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 113 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2016 | 959 | 0.040 |
Why?
|
| Gene Expression | 3 | 2017 | 3681 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 4067 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 322 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2002 | 596 | 0.040 |
Why?
|
| Proteogenomics | 1 | 2020 | 109 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 136 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4788 | 0.040 |
Why?
|
| Ovary | 4 | 1987 | 701 | 0.040 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Pyrazoles | 2 | 2019 | 1542 | 0.040 |
Why?
|
| Mitoxantrone | 2 | 1992 | 228 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4983 | 0.040 |
Why?
|
| Cholesterol | 1 | 2002 | 678 | 0.040 |
Why?
|
| Fever | 2 | 2002 | 515 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2019 | 7294 | 0.040 |
Why?
|
| Patient Selection | 3 | 2019 | 2042 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1998 | 31 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2020 | 2465 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 150 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 1338 | 0.040 |
Why?
|
| Vitamin A Deficiency | 1 | 1997 | 22 | 0.040 |
Why?
|
| Transposases | 1 | 2018 | 69 | 0.040 |
Why?
|
| Thalidomide | 1 | 2001 | 600 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 66 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 700 | 0.040 |
Why?
|
| Filgrastim | 1 | 1998 | 194 | 0.040 |
Why?
|
| Dasatinib | 2 | 2012 | 881 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 335 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 219 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2002 | 1056 | 0.040 |
Why?
|
| Cell Line | 6 | 1987 | 5437 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 747 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2021 | 2851 | 0.040 |
Why?
|
| Granulocytes | 1 | 1998 | 243 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2009 | 749 | 0.040 |
Why?
|
| Mesna | 2 | 2002 | 67 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2004 | 1255 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 744 | 0.030 |
Why?
|
| Cell Division | 3 | 1992 | 2716 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2018 | 958 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 741 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2000 | 683 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1998 | 738 | 0.030 |
Why?
|
| Biomarkers | 2 | 2018 | 5106 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 272 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 742 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 3655 | 0.030 |
Why?
|
| Pteridines | 1 | 2015 | 35 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 537 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4331 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2000 | 484 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 911 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2015 | 85 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 1135 | 0.030 |
Why?
|
| Vincristine | 4 | 1995 | 1572 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 791 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2009 | 753 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 535 | 0.030 |
Why?
|
| Aminopterin | 2 | 1992 | 32 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2013 | 3648 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 922 | 0.030 |
Why?
|
| Thiophenes | 1 | 2015 | 149 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1543 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1726 | 0.030 |
Why?
|
| Farnesyltranstransferase | 2 | 2005 | 125 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2013 | 4985 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 229 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2015 | 233 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 59 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1994 | 55 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 852 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 272 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 1269 | 0.030 |
Why?
|
| Brain Neoplasms | 4 | 2003 | 4983 | 0.030 |
Why?
|
| Cyclophosphamide | 5 | 1995 | 3231 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2018 | 864 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2014 | 208 | 0.030 |
Why?
|
| Cadherins | 1 | 2017 | 677 | 0.030 |
Why?
|
| Cell Cycle | 3 | 2012 | 2151 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1021 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 1995 | 134 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 209 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2018 | 1269 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 6465 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 745 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 879 | 0.030 |
Why?
|
| Alkalies | 1 | 1992 | 29 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1997 | 1482 | 0.030 |
Why?
|
| Ribonucleases | 1 | 1992 | 98 | 0.030 |
Why?
|
| United States | 3 | 2019 | 15982 | 0.030 |
Why?
|
| Magnesium | 2 | 2001 | 173 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1473 | 0.030 |
Why?
|
| Organelles | 1 | 1992 | 46 | 0.030 |
Why?
|
| Parotid Gland | 1 | 2012 | 117 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 594 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 1368 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 1567 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2012 | 219 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1992 | 148 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2012 | 125 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2012 | 163 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 171 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1992 | 255 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 320 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1934 | 0.020 |
Why?
|
| Sirolimus | 1 | 2016 | 831 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 185 | 0.020 |
Why?
|
| DNA Primers | 1 | 1994 | 1508 | 0.020 |
Why?
|
| CHO Cells | 1 | 1992 | 323 | 0.020 |
Why?
|
| Stomatitis | 1 | 2012 | 193 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 3267 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 954 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 4881 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 3172 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2017 | 1030 | 0.020 |
Why?
|
| Isotretinoin | 2 | 2002 | 161 | 0.020 |
Why?
|
| Agranulocytosis | 2 | 2004 | 83 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 6789 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1153 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 420 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 374 | 0.020 |
Why?
|
| Injections, Intralesional | 2 | 2002 | 166 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 324 | 0.020 |
Why?
|
| Mercaptoethanol | 1 | 1990 | 16 | 0.020 |
Why?
|
| Genes | 1 | 1992 | 611 | 0.020 |
Why?
|
| Hydroxyurea | 2 | 2004 | 223 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Leukopenia | 2 | 2004 | 153 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 357 | 0.020 |
Why?
|
| Proteolysis | 1 | 2012 | 380 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 686 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 480 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 474 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 257 | 0.020 |
Why?
|
| Liposomes | 2 | 2002 | 713 | 0.020 |
Why?
|
| Urologic Diseases | 1 | 1990 | 84 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 352 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2012 | 560 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2000 | 451 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 428 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 1988 | 36 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1409 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7951 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 726 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1992 | 663 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 572 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 685 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2012 | 6483 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 1586 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1510 | 0.020 |
Why?
|
| Texas | 1 | 2019 | 6415 | 0.020 |
Why?
|
| Metalloporphyrins | 1 | 2007 | 31 | 0.020 |
Why?
|
| Ribavirin | 1 | 1988 | 177 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1070 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 875 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1260 | 0.020 |
Why?
|
| Base Sequence | 1 | 1994 | 5496 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 601 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 2515 | 0.020 |
Why?
|
| Fatigue | 2 | 2004 | 1277 | 0.020 |
Why?
|
| Drug Evaluation | 3 | 1992 | 435 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2562 | 0.020 |
Why?
|
| Anthraquinones | 1 | 1986 | 28 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1934 | 0.020 |
Why?
|
| Abdomen | 1 | 2008 | 348 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2012 | 5782 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4732 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1740 | 0.020 |
Why?
|
| Glossectomy | 1 | 2005 | 43 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 134 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 157 | 0.020 |
Why?
|
| Adenylyl Imidodiphosphate | 1 | 1984 | 3 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 182 | 0.010 |
Why?
|
| Cell Movement | 1 | 2012 | 2500 | 0.010 |
Why?
|
| Ditiocarb | 1 | 1984 | 4 | 0.010 |
Why?
|
| Thiocarbamates | 1 | 1984 | 18 | 0.010 |
Why?
|
| Nucleotides | 1 | 1984 | 174 | 0.010 |
Why?
|
| Disulfiram | 1 | 1984 | 38 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 87 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3416 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 176 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2008 | 1043 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1984 | 623 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5438 | 0.010 |
Why?
|
| Temperature | 1 | 1984 | 541 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5843 | 0.010 |
Why?
|
| Child | 2 | 2017 | 30418 | 0.010 |
Why?
|
| Antibodies, Viral | 2 | 2000 | 1295 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 725 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1984 | 594 | 0.010 |
Why?
|
| Orbit | 1 | 2003 | 209 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7461 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5837 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1993 | 1913 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2001 | 41 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 2001 | 130 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 362 | 0.010 |
Why?
|
| Vitamin E | 1 | 2001 | 131 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2002 | 336 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 2001 | 59 | 0.010 |
Why?
|
| Caffeine | 1 | 2001 | 97 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1999 | 170 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 373 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 191 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 388 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 6027 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 465 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 751 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 442 | 0.010 |
Why?
|
| Leukemia | 1 | 1987 | 1720 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1994 | 4774 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1998 | 61 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1999 | 763 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1999 | 481 | 0.010 |
Why?
|
| Neoplasm Proteins | 2 | 2003 | 3349 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 5496 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1329 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 4644 | 0.010 |
Why?
|
| Kinetics | 2 | 1987 | 2247 | 0.010 |
Why?
|
| Leucovorin | 1 | 1992 | 343 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1994 | 16186 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1987 | 44 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 291 | 0.000 |
Why?
|
| Teniposide | 1 | 1984 | 4 | 0.000 |
Why?
|
| Benzoic Acid | 1 | 1984 | 4 | 0.000 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1984 | 33 | 0.000 |
Why?
|
| Plasmids | 1 | 1986 | 952 | 0.000 |
Why?
|
| NADP | 1 | 1984 | 91 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1997 | 8591 | 0.000 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1984 | 108 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1984 | 310 | 0.000 |
Why?
|
| Interleukin-2 | 1 | 1987 | 891 | 0.000 |
Why?
|
| Cattle | 1 | 1984 | 846 | 0.000 |
Why?
|
| Benzoates | 1 | 1984 | 130 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1984 | 1011 | 0.000 |
Why?
|
| HeLa Cells | 1 | 1986 | 1719 | 0.000 |
Why?
|
| DNA Replication | 1 | 1986 | 772 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1987 | 3083 | 0.000 |
Why?
|